Erik C Böttger Selected Research

Aminoglycosides

11/2021	Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis.
1/2021	Synthesis and Antibacterial Activity of Propylamycin Derivatives Functionalized at the 5''- and Other Positions with a View to Overcoming Resistance Due to Aminoglycoside Modifying Enzymes.
1/2020	Apralogs: Apramycin 5-O-Glycosides and Ethers with Improved Antibacterial Activity and Ribosomal Selectivity and Reduced Susceptibility to the Aminoacyltranserferase (3)-IV Resistance Determinant.
1/2020	Aminoglycosides: Time for the Resurrection of a Neglected Class of Antibacterials?
1/2019	In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii.
1/2019	Design, Multigram Synthesis, and in Vitro and in Vivo Evaluation of Propylamycin: A Semisynthetic 4,5-Deoxystreptamine Class Aminoglycoside for the Treatment of Drug-Resistant Enterobacteriaceae and Other Gram-Negative Pathogens.
1/2018	Effects of the 1- N-(4-Amino-2 S-hydroxybutyryl) and 6'- N-(2-Hydroxyethyl) Substituents on Ribosomal Selectivity, Cochleotoxicity, and Antibacterial Activity in the Sisomicin Class of Aminoglycoside Antibiotics.
11/2014	In vivo efficacy of apramycin in murine infection models.
9/2014	Identification and evaluation of improved 4'-O-(alkyl) 4,5-disubstituted 2-deoxystreptamines as next-generation aminoglycoside antibiotics.
7/2012	Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Erik C Böttger Research Topics

Disease

24	Tuberculosis (Tuberculoses) 07/2021 - 10/2002
20	Infections 01/2022 - 10/2008
10	Ototoxicity 01/2021 - 12/2008
9	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 07/2021 - 02/2008
4	Sepsis (Septicemia) 11/2020 - 11/2014
4	Communicable Diseases (Infectious Diseases) 01/2020 - 12/2011
4	Bacterial Infections (Bacterial Infection) 01/2020 - 12/2011
4	Hearing Loss (Hearing Impairment) 09/2014 - 12/2008
3	Extensively Drug-Resistant Tuberculosis 02/2014 - 04/2012
2	Genomic Instability 07/2008 - 05/2008
1	Lymphopenia (Lymphocytopenia) 01/2022
1	Premature Aging 01/2022
1	Mitochondrial Diseases (Mitochondrial Disease) 12/2021
1	Pyelonephritis 11/2021
1	Urinary Tract Infections (Urinary Tract Infection) 11/2021
1	Muscular Atrophy (Muscle Atrophy) 01/2021
1	HIV Infections (HIV Infection) 01/2020
1	Persistent Infection 09/2015
1	Pneumococcal Pneumonia 05/2015
1	Escherichia coli Infections 10/2014
1	Nontuberculous Mycobacterium Infections 11/2012
1	Hypersensitivity (Allergy) 06/2011
1	Parasitic Diseases (Parasitic Disease) 05/2011
1	Deafness (Deaf Mutism) 12/2008
1	Aminoglycoside-Induced Deafness 12/2008

Drug/Important Bio-Agent (IBA)

17	Pharmaceutical PreparationsIBA 11/2021 - 02/2008
15	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 05/2011
15	AminoglycosidesIBA 11/2021 - 12/2008
6	apramycinIBA 11/2021 - 07/2012
5	Paromomycin (Paromomycin Sulfate)FDA LinkGeneric 01/2019 - 05/2011
4	Amikacin (A.M.K)FDA LinkGeneric 01/2022 - 04/2012
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 12/2008
3	VaccinesIBA 03/2015 - 10/2003
2	Gentamicins (Gentamicin)FDA LinkGeneric 11/2021 - 01/2018
2	propylamycinIBA 01/2021 - 01/2019
2	Rifampin (Rifampicin)FDA LinkGeneric 01/2020 - 07/2017
2	bedaquiline (R207910)IBA 11/2015 - 07/2015
2	OPC-67683IBA 11/2015 - 07/2015
2	Clarithromycin (Biaxin)FDA LinkGeneric 09/2015 - 11/2012
2	Metalloproteases (Metalloproteinases)IBA 03/2015 - 06/2011
2	ZincIBA 03/2015 - 06/2011
2	Rifabutin (Ansamycin)FDA Link 01/2015 - 01/2013
2	AerosolsIBA 11/2014 - 06/2012
2	DNA (Deoxyribonucleic Acid)IBA 07/2013 - 05/2012
2	Codon (Codons)IBA 01/2013 - 05/2008
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022
1	AminesIBA 11/2021
1	Carbapenems (Carbapenem Antibiotics)IBA 09/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	IsoenzymesIBA 01/2021
1	GlucocorticoidsIBA 01/2021
1	EnzymesIBA 01/2019
1	TransferasesIBA 01/2019
1	AgarIBA 01/2019
1	Tobramycin (Nebcin)FDA LinkGeneric 01/2018
1	plazomicinIBA 01/2018
1	TAM16 compoundIBA 07/2017
1	Isoniazid (Ftivazide)FDA LinkGeneric 07/2017
1	RifamycinsIBA 01/2017
1	Antitubercular AgentsIBA 01/2017
1	spectinamide 1599IBA 09/2015
1	beta-Lactamases (beta-Lactamase)IBA 10/2014
1	Amoxicillin-Potassium Clavulanate Combination (Co-amoxiclav)FDA Link 10/2014
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 10/2014
1	Spectinomycin (Spectinomycin Hydrochloride)FDA Link 02/2014
1	Bacterial Proteins (Bacterial Protein)IBA 02/2014
1	2-deoxystreptamineIBA 07/2012
1	Moxifloxacin (Avelox)FDA Link 05/2012
1	Kanamycin FDA Link 04/2012
1	InterferonsIBA 04/2012
1	Peptides (Polypeptides)IBA 04/2012
1	Capreomycin (Capastat)FDA Link 04/2012
1	Ethionamide (Trecator-SC)FDA Link 02/2012
1	Ethambutol (Myambutol)FDA LinkGeneric 01/2012
1	16S Ribosomal RNAIBA 12/2011
1	tuberactinomycinIBA 10/2011
1	Interferon-gamma (Interferon, gamma)IBA 06/2011
1	AntigensIBA 06/2011
1	23S Ribosomal RNAIBA 03/2009
1	tiamulinIBA 03/2009
1	Ribosomal Protein L3IBA 03/2009
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 12/2008
1	signal peptidase II (premurein-leader peptidase)IBA 10/2008
1	NucleotidesIBA 05/2008
1	PorinsIBA 10/2002

Therapy/Procedure

11	Therapeutics 01/2022 - 07/2012
1	Heart-Lung Machine 10/2015
1	Extracorporeal Circulation 07/2015
1	Injections 04/2012
1	Drug Therapy (Chemotherapy) 02/2008